Insulet plans label expansion for Omnipod in type 2 diabetes [Yahoo! Finance]
Insulet Corporation (PODD)
Last insulet corporation earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insulet.com/investor-relations
Company Research
Source: Yahoo! Finance
The company shared the results from the open-label SECURE-T2D clinical trial (NCT05815342) that evaluated the safety and efficacy of Omnipod 5. Insulet has also submitted the data to the US Food and Drug Administration (FDA) to expand Omnipod 5's indication for use in the type 2 diabetes population. If approved, the company plans to launch the Omnipod 5 for type 2 diabetes use in the US early next year. The diabetes care market is expected to grow to be worth $33.5bn in 2030, as per the GlobalData market model. This growth will be mostly driven by insulin delivery devices , with these devices market is forecasted to generate $25.6bn in 2030. GlobalData is the parent company of Clinical Trials Arena Omnipod 5 is cleared by the US FDA and has a European CE mark for use in patients aged two years and older with type 1 diabetes. The device can pair with a continuous glucose monitor (CGM), including the Dexcom G6 CGM system and Abbott FreeStyle Libre, to automatically adjust insul
Show less
Read more
Impact Snapshot
Event Time:
PODD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PODD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PODD alerts
High impacting Insulet Corporation news events
Weekly update
A roundup of the hottest topics
PODD
News
- ESLOY vs. PODD: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes [Yahoo! Finance]Yahoo! Finance
- Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes [Yahoo! Finance]Yahoo! Finance
- Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 DiabetesBusiness Wire
- Insulet (PODD) Faces Increasing Competition [Yahoo! Finance]Yahoo! Finance
PODD
Earnings
- 5/9/24 - Beat
PODD
Sec Filings
- 6/25/24 - Form 144
- 6/17/24 - Form 4
- 6/14/24 - Form 144
- PODD's page on the SEC website